Alteogen FY 2025 Annual ReportBeta
Alteogen annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Alteogen FY 2025 Annual Report Analysis
Business Overview
- • Platform biotech licensing IV-to-SC hyaluronidase tech (Hybrozyme™/ALT-B4) to MSD, AstraZeneca, GSK, Daiichi Sankyo, Sandoz; revenue via upfront, milestones, royalties
- • Total revenue KRW 215.9B in FY2025, up 110% YoY from KRW 102.9B; tech licensing revenue KRW 169.4B (78.5% of total), up ~124% YoY
Management Discussion & Analysis
- • Alteogen (알테오젠) FY2025 revenue KRW 215.9B (+109.9% YoY); operating profit KRW 106.9B (+320.8%); net income KRW 145.2B (+139.2%)
- • Growth driven by ALT-B4 license upfront payments from multinational pharma partners (MSD, AstraZeneca, GSK, Daiichi Sankyo, Sandoz)
Risk Factors
- • FX sensitivity: 10% move in USD/EUR rates impacts pre-tax profit by ±KRW 21.5B (current year) vs ±KRW 5.3B (prior year) — 4x increase in FX exposure YoY
- • Foreign currency financial assets KRW 230.9B vs liabilities KRW 16.1B; net long USD/EUR position dominated by USD 104.6M in short-term financial instruments
Alteogen FY 2025 Key Financial MetricsDART
Total Assets
KRW 698.7B
▲ +70.8% YoY
Operating Cash Flow
KRW 124.1B
▲ +134.0% YoY
CapEx
KRW 23.0B
▲ +746.3% YoY
Source: KIFRS consolidated financial data from Alteogen annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding